CD8A and neoplasm: However, these advances are constrained by immune suppression within the tumor microenvironment (TME), such as Adora2b-mediated adenosine signaling inhibiting CD8+ T cell infiltration, resulting in approximately 50% of PD-L1-positive patients failing to benefit (6, 7).